Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Dec 1, 2021 (5 years ago)

Telmisartan and Hydrochlorothiazide Tablets

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Superpotent; Hydrochlorothiazide

Cause type: Wrong potency / content

Sub- or super-potent product, or a failed content-uniformity / assay test. You may receive too little or too much active ingredient - a direct dosing risk. All wrong potency / content recalls.

What was recalled

Telmisartan and Hydrochlorothiazide Tablets, USP, 40 mg/12.5 mg, 30 count bottles, Rx only, Manufactured by: Torrent Pharmaceuticals LTD., Indrad-382 721, India. Manufactured for: Torrent Pharma Inc., Basking Ridge, NJ 07920. NDC: 13668-159-30

Affected NDC 13668-0159-30

Compare with the code on your package — it is the most precise check available.

Drug: Hydrochlorothiazide Category: Blood Pressure Medication

Recalling firm
Torrent Pharma Inc.
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0285-2022 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Hydrochlorothiazide recalls

See all
Class II · Moderate risk

Lisinopril and Hydrochlorothiazide Tablets USP 20mg/12.5mg

Product Mix Up: This product is being recalled because of a complaint received that a sealed bottle of lisinopril and hydrochlorothiazide tablets 20mg/12.5 mg had a foreign tablet identified as atazanavir and ritonavir tablet 300mg/100mg.

Ongoing Labeling / mix-up Lupin Pharmaceuticals Inc. NDC 68180-519-01 D-0532-2025

Other recalls by Torrent Pharma Inc.

All 2021 recalls
Class II · Moderate risk

Fluoxetine Tablets

CGMP Deviations: Presence of N-Nitroso Fluoxetine exceeding interim acceptable intake limit.

Completed Nitrosamine impurity Torrent Pharma Inc. D-0456-2025
Class II · Moderate risk

Fluoxetine Tablets

CGMP Deviations: Presence of N-Nitroso Fluoxetine exceeding interim acceptable intake limit.

Completed Nitrosamine impurity Torrent Pharma Inc. D-0455-2025